Catalysts / HURA
Upcoming FDA decisions and readouts we track for TuHURA Biosciences, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for TuHURA Biosciences (HURA, listed on Nasdaq). They cover 2 programmes: IFx-2.0 + pembrolizumab (Deep-seated Merkel cell carcinoma) and TBS-2025 (NPM1-mutated relapsed/refractory AML (VISTA antibody)).
First on the list: the Clinical readout for IFx-2.0 + pembrolizumab (Deep-seated Merkel cell carcinoma), guided by the company to H1 2027. By stage, the upcoming rows are 1 Phase 1 readout and 1 Clinical readout.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| TuHURA Biosciences HURA · Nasdaq | IFx-2.0 + pembrolizumab | Deep-seated Merkel cell carcinoma | H1 2027 company guidance |
Clinical readout | Verified | 8-K exhibit 99.1 ↗ | No |
| TuHURA Biosciences HURA · Nasdaq | TBS-2025 | NPM1-mutated relapsed/refractory AML (VISTA antibody) | H1 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList